Netherlands Cancer Institute
Amsterdam, Netherlands
After finishing medical school in 2008, Myriam Chalabi did her residency in internal medicine and continued her oncology specialization at the Ntherlands Cancer Institute in Amsterdam. In 2016 she became staff member at the Netherlands Cancer Institute in Amsterdam as a Gastrointestinal Oncologist and clinician scientist. In 2022 she was named one of the 11 early career researchers to watch by Nature Medicine and in 2023 she received the ESMO Jose Baselga Fellowship for Clinical Scientists. She is the lead investigator (PI) of several neoadjuvant immunotherapy trials in gastrointestinal cancers, including the globally renowned NICHE study, in which patients with colon cancers were found to have impressive responses after a short duration of neoadjuvant immunotherapy. Her research focuses on early innovative combination immunotherapy trials with a strong focus on translational research to better understand the drivers of response in these tumors and find novel immunotherapy combinations. Her main goal is to improve immunotherapy for patients with gastrointestinal cancers.
Opportunities and Challenges of Building Trials in Rarer GI Subtypes
Thursday, June 29, 2023
09:00 – 09:15 CEST
Thursday, June 29, 2023
09:15 – 09:25 CEST